Intravenous apoptotic cell infusion as a cell-based therapy toward improving hematopoietic cell transplantation outcome

Annals of the New York Academy of Sciences

Volumn 1209, Issue 1, 2010, Pages 118-126

  Saas, Philippe ^a,b,c   Gaugler, Béatrice ^a,b,c   Perruche, Sylvain ^a,b,c  

^a INSERM   (France)

^b UNIVERSITÉ DE FRANCHE COMTÉ   (France)

^c ETABLISSEMENT FRANÇAIS DU SANG   (France)

Author keywords

Apoptotic cells; Graft versus host disease; Hematopoietic cell transplantation; Macrophage; Regulatory T cells; TGF

Indexed keywords

ALLOANTIBODY; CYCLOSPORIN A; FLUDARABINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; RITUXIMAB; T LYMPHOCYTE RECEPTOR; THYMOCYTE ANTIBODY; TRANSFORMING GROWTH FACTOR BETA;

ACUTE GRAFT REJECTION; ACUTE GRAFT VERSUS HOST DISEASE; ALLERGIC ENCEPHALOMYELITIS; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOIMMUNIZATION; APOPTOSIS; APOPTOTIC LEUKOCYTE INFUSION; ARTICLE; CD4+ T LYMPHOCYTE; CELL THERAPY; CHRONIC GRAFT REJECTION; CHRONIC GRAFT VERSUS HOST DISEASE; CONTACT ALLERGY; DIABETES MELLITUS; DISEASE SEVERITY; ENGRAFTMENT; GRAFT REJECTION; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; NATURAL KILLER CELL; NONMYELOABLATIVE CONDITIONING; PHOTOCHEMOTHERAPY; REDUCED INTENSITY CONDITIONING; REGULATORY T LYMPHOCYTE; SEPSIS; T LYMPHOCYTE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; REVIEW; TREATMENT OUTCOME;

APOPTOSIS; GRAFT REJECTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME;

EID: 78049508713     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2010.05741.x     Document Type: Article

References (82)

1. Appelbaum, F.R. 2007. Hematopoietic-cell transplantation at 50. N. Engl. J. Med. 357: 1472-1475.
2. Gluckman, E. et al 1989. Hematopoietic reconstitution in a patient with Fanconi's anemia by means of umbilical-cord blood from an HLA-identical sibling. N. Engl. J. Med. 321: 1174-1178.
3. Lekakis, L. et al 2006. Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies. Bone Marrow Transplant. 38: 421-426.
4. Jabbour, E. et al 2007. Treatment of donor graft failure with nonmyeloablative conditioning of fludarabine, antithymocyte globulin and a second allogeneic hematopoietic transplantation. Bone Marrow Transplant. 40: 431-435.
5. Mizutani, E. et al 2007. Successful second cord blood transplantation using fludarabine and cyclophosphamide as a preparative regimen for graft rejection following reduced-intensity cord blood transplantation. Bone Marrow Transplant. 40: 85-87.
6. Nakamura, Y. et al 2007. Successful engraftment of the second reduced-intensity conditioning cord blood transplantation (CBT) for a patient who developed graft rejection and infectious complications after the first CBT for AML. Bone Marrow Transplant. 40: 395-396.
7. Takagi, S. et al 2009. High incidence of haemophagocytic syndrome following umbilical cord blood transplantation for adults. Br. J. Haematol. 147: 543-553.
8. Slavin, S. et al 1998. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 91: 756-763.
9. McSweeney, P.A. et al 2001. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 97: 3390-3400.
10. Fudaba, Y. et al 2006. Myeloma responses and tolerance following combined kidney and nonmyeloablative marrow transplantation: in vivo and in vitro analyses. Am. J. Transplant. 6: 2121-2133.
11. Blaise, D. et al 2004. Reduced-intensity preparative regimen and allogeneic stem cell transplantation for advanced solid tumors. Blood 103: 435-441.
12. Childs, R.W. et al 1999. Successful treatment of metastatic renal cell carcinoma with a nonmyeloablative allogeneic peripheral-blood progenitor-cell transplant: evidence for a graft-versus-tumor effect. J. Clin. Oncol. 17: 2044-2049.
13. Clave, E. et al 2009. Acute graft-versus-host disease transiently impairs thymic output in young patients after allogeneic hematopoietic stem cell transplantation. Blood 113: 6477-6484.
14. Green, D.R. et al 2009. Immunogenic and tolerogenic cell death. Nat. Rev. Immunol. 9: 353-363.
15. Morelli, A.E. & A.T. Larregina 2010. Apoptotic cell-based therapies against transplant rejection: role of recipient's dendritic cells. Apoptosis. 15: 1083-1097.
16. Mattsson, J., O. Ringden & R. Storb 2008. Graft failure after allogeneic hematopoietic cell transplantation. Biol. Blood Marrow Transplant. 14: 165-170.
17. Bittencourt, M.C. et al 2001. Intravenous injection of apoptotic leukocytes enhances bone marrow engraftment across major histocompatibility barriers. Blood 98: 224-230.
18. Kleinclauss, F. et al 2003. Administration of donor apoptotic cells: an alternative cell-based therapy to induce tolerance? Transplantation 75: 43S-45S.
19. Niederwieser, D. et al 2003. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood 101: 1620-1629.
20. Maris, M. et al 2003. Immunologic recovery after hematopoietic cell transplantation with nonmyeloablative conditioning. Exp. Hematol. 31: 941-952.
21. Maris, M.B. et al 2003. HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. Blood 102: 2021-2030.
22. Laughlin, M.J. et al 2001. Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. N. Engl. J. Med. 344: 1815-1822.
23. Maraninchi, D. et al 1987. Impact of T-cell depletion on outcome of allogeneic bone-marrow transplantation for standard-risk leukaemias. Lancet 2: 175-178.
24. Marmont, A.M. et al 1991. T-cell depletion of HLA-identical transplants in leukemia. Blood 78: 2120-2130.
25. Martin, P.J. 2000. Winning the battle of graft versus host. Nat. Med. 6: 18-19.
26. Taylor, P.A. et al 2007. Preformed antibody, not primed T cells, is the initial and major barrier to bone marrow engraftment in allosensitized recipients. Blood 109: 1307-1315.
27. Spellman, S. et al 2010. The detection of donor-directed, HLA-specific alloantibodies in recipients of unrelated hematopoietic cell transplantation is predictive of graft failure. Blood 115: 2704-2708.
28. Kleinclauss, F. et al 2006. Intravenous apoptotic spleen cell infusion induces a TGF-beta-dependent regulatory T-cell expansion. Cell Death Differ. 13: 41-52.
29. Perruche, S. et al 2004. Intravenous infusion of apoptotic cells simultaneously with allogeneic hematopoietic grafts alters anti-donor humoral immune responses. Am. J. Transplant. 4: 1361-1365.
30. Fadok, V.A. et al 1998. Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF. J. Clin. Invest. 101: 890-898.
31. Huynh, M.L., V.A. Fadok & P.M. Henson 2002. Phosphatidylserine-dependent ingestion of apoptotic cells promotes TGF-beta1 secretion and the resolution of inflammation. J. Clin. Invest. 109: 41-50.
32. Kim, J.M., J.P. Rasmussen & A.Y. Rudensky 2007. Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice. Nat. Immunol. 8: 191-197.
33. Ochando, J.C. et al 2006. Alloantigen-presenting plasmacytoid dendritic cells mediate tolerance to vascularized grafts. Nat. Immunol. 7: 652-662.
34. Ren, Y. et al 2008. Apoptotic cells protect mice against lipopolysaccharide-induced shock. J. Immunol. 180: 4978-4985.
35. Lucas, M. et al 2003. Apoptotic cells and innate immune stimuli combine to regulate macrophage cytokine secretion. J. Immunol. 171: 2610-2615.
36. Serinkan, B.F. et al 2005. Apoptotic cells quench reactive oxygen and nitrogen species and modulate TNF-alpha/TGF-beta1 balance in activated macrophages: involvement of phosphatidylserine-dependent and -independent pathways. Cell Death Differ. 12: 1141-1144.
37. Stuart, L.M. et al 2002. Inhibitory effects of apoptotic cell ingestion upon endotoxin-driven myeloid dendritic cell maturation. J. Immunol. 168: 1627-1635.
38. Krispin, A. et al 2006. Apoptotic cell thrombospondin-1 and heparin-binding domain lead to dendritic-cell phagocytic and tolerizing states. Blood 108: 3580-3589.
39. Bonnefoy, F. et al 2008. Sirolimus enhances the effect of apoptotic cell infusion on hematopoietic engraftment and tolerance induction. Leukemia 22: 1430-1434.
40. Wu, Y. et al 2006. FOXP3 controls regulatory T cell function through cooperation with NFAT. Cell 126: 375-387.
41. Perruche, S. et al 2008. CD3-specific antibody-induced immune tolerance involves transforming growth factor-beta from phagocytes digesting apoptotic T cells. Nat. Med. 14: 528-535.
42. Saas, P. et al 2007. Mediators involved in the immunomodulatory effects of apoptotic cells. Transplantation 84: S31-S34.
43. Chen, W. et al 2003. Conversion of peripheral CD4+CD25-naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J. Exp. Med. 198: 1875-1886.
44. Perruche, S. & P. Saas 2009. CD3-specific antibody-induced T-cell apoptosis and apoptotic cell uptake lead to CD3-specific antibody-induced tolerance. Med. Sci. (Paris) 25: 325-327.
45. Voll, R.E. et al 1997. Immunosuppressive effects of apoptotic cells. Nature 390: 350-351.
46. Perruche, S., P. Saas & W. Chen 2009. Apoptotic cell-mediated suppression of streptococcal cell wall-induced arthritis is associated with alteration of macrophage function and local regulatory T-cell increase: a potential cell-based therapy? Arthritis Res. Ther. 11: R104.
47. Dvorak, C.C., E. Callard & R. Agarwal 2006. Use of intravenous mycophenolate mofetil for graft-versus-host disease prophylaxis in an allogeneic hematopoietic stem cell transplant recipient with an allergic reaction to cyclosporine and tacrolimus. Bone Marrow Transplant. 38: 253-254.
48. Cutler, C. et al 2005. Sirolimus and thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation. Biol. Blood Marrow Transplant. 11: 551-557.
49. Busca, A. et al 2005. Sirolimus-related toxicity in stem cell transplantation. Biol. Blood Marrow Transplant. 11: 647-649.
50. Schleuning, M. et al 2009. Calcineurin inhibitor-free GVHD prophylaxis with sirolimus, mycophenolate mofetil and ATG in Allo-SCT for leukemia patients with high relapse risk: an observational cohort study. Bone Marrow Transplant. 43: 717-723.
51. Hsieh, M.M. et al 2009. Allogeneic hematopoietic stem-cell transplantation for sickle cell disease. N. Engl. J. Med. 361: 2309-2317.
52. Zhang, Y. et al 2002. APCs in the liver and spleen recruit activated allogeneic CD8+ T cells to elicit hepatic graft-versus-host disease. J. Immunol. 169: 7111-7118.
53. Socie, G. & B.R. Blazar 2009. Acute graft-versus-host disease: from the bench to the bedside. Blood 114: 4327-4336.
54. Shlomchik, W.D. 2007. Graft-versus-host disease. Nat. Rev. Immunol. 7: 340-352.
55. Ferrara, J.L. et al 2009. Graft-versus-host disease. Lancet 373: 1550-1561.
56. Xia, C.Q. et al 2007. Transfusion of apoptotic beta-cells induces immune tolerance to beta-cell antigens and prevents type 1 diabetes in NOD mice. Diabetes 56: 2116-2123.
57. Miyake, Y. et al 2007. Critical role of macrophages in the marginal zone in the suppression of immune responses to apoptotic cell-associated antigens. J. Clin. Invest. 117: 2268-2278.
58. Qiu, C.H. et al 2009. Novel subset of CD8{alpha}+ dendritic cells localized in the marginal zone is responsible for tolerance to cell-associated antigens. J. Immunol. 182: 4127-4136.
59. Gray, M.et al. 2007. Apoptotic cells protect mice from autoimmune inflammation by the induction of regulatory B cells. Proc. Natl. Acad. Sci. USA 104: 14080-14085.
60. Hotchkiss, R.S. et al 2003. Adoptive transfer of apoptotic splenocytes worsens survival, whereas adoptive transfer of necrotic splenocytes improves survival in sepsis. Proc. Natl. Acad. Sci. USA 100: 6724-6729.
61. Griffith, T.S. et al 2007. Apoptotic cells induce tolerance by generating helpless CD8+ T cells that produce TRAIL. J. Immunol. 178: 2679-2687.
62. Sun, E. et al 2004. Allograft tolerance induced by donor apoptotic lymphocytes requires phagocytosis in the recipient. Cell Death Differ. 11: 1258-1264.
63. Wang, Z. et al 2006. Use of the inhibitory effect of apoptotic cells on dendritic cells for graft survival via T-cell deletion and regulatory T cells. Am. J. Transplant. 6: 1297-1311.
64. Wang, Z. et al 2009. In situ-targeting of dendritic cells with donor-derived apoptotic cells restrains indirect allorecognition and ameliorates allograft vasculopathy. PLoS One 4: e4940.
65. Cohen, J.L. et al 2002. CD4(+)CD25(+) immunoregulatory T cells: new therapeutics for graft-versus-host disease. J. Exp. Med. 196: 401-406.
66. Hoffmann, P. et al 2002. Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J. Exp. Med. 196: 389-399.
67. Ermann, J. et al 2005. Only the CD62L+ subpopulation of CD4+CD25+ regulatory T cells protects from lethal acute GVHD. Blood 105: 2220-2226.
68. Taylor, P.A., C.J. Lees & B.R. Blazar 2002. The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood 99: 3493-3499.
69. Taylor, P.A. et al 2004. L-Selectin(hi) but not the L-selectin(lo) CD4 + 25+ T-regulatory cells are potent inhibitors of GVHD and BM graft rejection. Blood 104: 3804-3812.
70. Edinger, M. et al 2003. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat. Med. 9: 1144-1150.
71. Banovic, T. et al 2005. TGF-beta in allogeneic stem cell transplantation: friend or foe? Blood 106: 2206-2214.
72. Mohty, M. et al 2005. Inflammatory cytokines and acute graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation. Blood 106: 4407-4411.
73. Paczesny, S. et al 2009. A biomarker panel for acute graft-versus-host disease. Blood 113: 273-278.
74. Paczesny, S., S.W. Choi & J.L. Ferrara 2009. Acute graft-versus-host disease: new treatment strategies. Curr. Opin. Hematol. 16: 427-436.
75. Maeda, A. et al 2005. Intravenous infusion of syngeneic apoptotic cells by photopheresis induces antigen-specific regulatory T cells. J. Immunol. 174: 5968-5976.
76. Gatza, E. et al 2008. Extracorporeal photopheresis reverses experimental graft-versus-host disease through regulatory T cells. Blood 112: 1515-1521.
77. Rao, V. et al 2009. Cutaneous T cell lymphoma and graft-versus-host disease: a comparison of in vivo effects of extracorporeal photochemotherapy on Foxp3+ regulatory T cells. Clin. Immunol. 133: 303-313.
78. Li, N. et al 2009. Anti-CD3 preconditioning separates GVL from GVHD via modulating host dendritic cell and donor T-cell migration in recipients conditioned with TBI. Blood 113: 953-962.
79. Thaunat, O., E. Morelon & T. Defrance 2010. Am "B"valent: anti-CD20 antibodies unravel the dual role of B cells in immunopathogenesis. Blood 116: 515-521.
80. Lund, F.E. & T.D. Randall 2010. Effector and regulatory B cells: modulators of CD4(+) T cell immunity. Nat. Rev. Immunol. 10: 236-247.
81. Perruche, S. et al 2003. A single intravenous infusion of apoptotic cells, an alternative cell-based therapy approach facilitating hematopoietic cell engraftment, does not induce autoimmunity. J. Hematother. Stem Cell Res. 12: 451-459.
82. Torre-Amione, G. et al 2008. Results of a non-specific immunomodulation therapy in chronic heart failure (ACCLAIM trial): a placebo-controlled randomised trial. Lancet 371: 228-236.